A network meta-analysis of the antithrombotic strategies in patients with atrial fibrillation and percutaneous coronary interventions: Focus on bleeding

Colilla, 2013, Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population, Am J Cardiol, 112, 1142, 10.1016/j.amjcard.2013.05.063 Kamel, 2016, Atrial fibrillation and mechanisms of stroke: time for a new model, Stroke, 47, 895, 10.1161/STROKEAHA.115.012004 Borre, 2018, Predicting thromboembolic and bleeding event risk in patients with non-valvular atrial fibrillation: a systematic review, Thromb Haemostasis, 118, 2171, 10.1055/s-0038-1675400 Michniewicz, 2018, Patients with atrial fibrillation and coronary artery disease – Double trouble, Adv Med Sci, 63, 30, 10.1016/j.advms.2017.06.005 Valgimigli, 2018, Eur Heart J, 39, 213, 10.1093/eurheartj/ehx419 van Rein, 2019, Major bleeding rates in atrial fibrillation patients on single, dual, or triple antithrombotic therapy, Circulation, 139, 775, 10.1161/CIRCULATIONAHA.118.036248 Hutton, 2015, The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations, Ann Intern Med, 162, 777, 10.7326/M14-2385 Sterne, 2019, RoB 2: a revised tool for assessing risk of bias in randomised trials, BMJ, 366 Salanti, 2011, Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial, J Clin Epidemiol, 64, 163, 10.1016/j.jclinepi.2010.03.016 Dewilde, 2013, Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial, Lancet, 381, 1107, 10.1016/S0140-6736(12)62177-1 Gibson, 2016, Prevention of bleeding in patients with atrial fibrillation undergoing PCI, N Engl J Med, 375, 2423, 10.1056/NEJMoa1611594 Lopes, 2019, Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation, N Engl J Med, 380, 1509, 10.1056/NEJMoa1817083 Vranckx, 2019, Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial, Lancet, 394, 1335, 10.1016/S0140-6736(19)31872-0 Cannon, 2017, Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation, N Engl J Med, 377, 1513, 10.1056/NEJMoa1708454 Capodanno, 2020, Safety and efficacy of double antithrombotic therapy with non–vitamin k antagonist oral anticoagulants in patients with atrial fibrillation undergoing percutaneous coronary intervention: a systematic review and meta-analysis, J Am Heart Assoc, 9 Potpara, 2020, Revisiting the effects of omitting aspirin in combined antithrombotic therapies for atrial fibrillation and acute coronary syndromes or percutaneous coronary interventions: meta-analysis of pooled data from the PIONEER AF-PCI, RE-DUAL PCI, and AUGUSTUS tr, Europace, 22, 33, 10.1093/europace/euz259 Gargiulo, 2019, Safety and efficacy outcomes of double vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of non-Vitamin K antagonist oral anticoagulant-based randomiz, Eur Heart J, 40, 3757, 10.1093/eurheartj/ehz732